The main exclusion criteria were hemorrhagic stroke or history of symptomatic hemorrhagic stroke; presence of high-risk potential cardiac sources of embolism or other determined etiology of stroke based on the Trial of Org 10,172 in Acute Stroke Treatment classification at the time of enrollment; known major hematologic, neoplastic, metabolic, gastrointestinal, or endocrine dysfunction; history of malignancy, except in subjects who had been disease-free > 5 years or whose only malignancy has been basal or squamous cell skin carcinoma; life-threatening illness indicating that the subject is not expected to survive for at least 2 years; secondary causes of nephrotic syndrome and/or renal dysfunction (serum creatinine > 2.0 mg/dL); uncontrolled hypertension defined as either a resting systolic blood pressure > 185 mmHg or resting diastolic blood pressure > 110 mmHg despite blood pressure lowering therapy; clinically significant heart disease likely to require coronary artery bypass surgery, cardiac transplantation, surgical repair, and/or valve replacement during the course of the study (within 14 days after enrollment); moderate or greater severity of congestive heart failure (New York Heart Association Class III or IV) or whose most recent determination of left ventricular ejection fraction was < 0.35; triglyceride level > 500 mg/dL; low-density lipoprotein (LDL) cholesterol level > 190 mg/dL; creatine kinase > 3 times the upper limit of normal range (ULN); aspartate aminotransferase, alanine aminotransferase, or bilirubin levels > 3 times the ULN; thyroid stimulating hormone > 1.5 times the ULN; modified Rankin scale score 4-6 before stroke; possible need for conventional angiography, intervention, or carotid artery surgery during the course of the study; known serious hypersensitivity reactions to HMG-CoA reductase inhibitors; and history of myopathy.
Conduct of study
The first patient was enrolled in August 2010, and the study was scheduled to complete enrollment in August 2012. However, in June 2013 the study was stopped early due to slow enrollment. All patient data were recorded on standardized data-collection forms by an investigator or coordinator who was unaware of study-group assignments. All data were subsequently entered into a web-based clinical data management system and managed by an independent data management service (ADM Korea Inc., Seoul, Korea). 
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